"We see potential for zuranolone, if approved, to be a meaningful new option that can help address the serious unmet need faced by the diverse populations struggling with MDD and PPD," said Dr. Priya Singhal, executive vice president at Biogen, which partnered with Sage Therapeutics to develop the treatment.
The companies say the medication targets brain networks responsible for functions such as mood, arousal, behavior, and cognition. Their application has been granted priority review and the FDA is expected to deliver a decision on Aug. 5. #postpartum #depression #scrippsnews
-------------------------------------
Scripps News is your source for news and analysis covering the top stories from around the world. With persistent curiosity and no agenda, we strive to fuel meaningful conversations by highlighting multiple sides of every story. It’s news with the why.
Join our newsletter at [ Ссылка ]
See more at [ Ссылка ]
Like Newsy on Facebook: [ Ссылка ]
Follow us on Twitter: [ Ссылка ]
